Christine M. Lovly, MD, PhD, discusses the changing treatment landscape for patients with EGFR-mutant and ALK-positive NSCLC.
Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners
Latest from Vanderbilt-Ingram Cancer Center
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
Dr Mayer on the FDA Approval of Camizestrant for ESR1-Mutated Breast Cancer
3
INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management
4
Dr Barot on CNS Outcomes With Palbociclib in HER2+ Breast Cancer
5